Stefan Moore, Chairman and CEO of Cancer Response Team, shared a post on X:
“A deadly glioblastoma that’s long defied treatment just showed extraordinary responses in a Mass General trial that’s giving hope for Brain Cancer.
Next-gen CAR-T therapy (dual-targeting EGFRvIII + wild-type EGFR) after one single infusion, all initial patients saw rapid tumor shrinkage, one nearly vanished, another ~60% reduction lasting months.
Responses were temporary, but this proves a single dose can unleash powerful attacks on these tough tumors. Early days (phase 1 trial ongoing, more patients treated with promising safety), but a major step forward for immunotherapy in solid brain cancers.
Source: Mass General / NEJM.”
More posts featuring Stefan Moore.